Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12779/6956
DC FieldValueLanguage
dc.contributor.authorManetti, Fabrizioen_us
dc.date.accessioned2021-03-30T16:07:19Z-
dc.date.available2021-03-30T16:07:19Z-
dc.date.issued2018-
dc.identifier.issn0223-5234en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12779/6956-
dc.description151392en_US
dc.language.isoenen_US
dc.relationNoneen_US
dc.relation.ispartofEUROPEAN JOURNAL OF MEDICINAL CHEMISTRYen_US
dc.subjectLIM domain kinases, Inhibitors, Structure-activity relationships, Rational design, Anticancer, Intra-ocular pressureen_US
dc.titleRecent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trialsen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ejmech.2018.06.016en_US
dc.identifier.pmid29908439en_US
dc.identifier.scopus2-s2.0-85048424523en_US
dc.identifier.isiWOS:000441856300035en_US
dc.relation.volume155en_US
dc.description.firstpage445en_US
dc.description.lastpage458en_US
dc.description.thirdmissionNot applicableen_US
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeArticle-
item.fulltextNo Fulltext-
crisitem.author.orcid0000-0002-9598-2339-
Appears in Collections:Publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.